Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 73 of the 79 references it cites were found in a registry or an index; 36 of the 58 sources its claims cite were checked for support.

Neuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrum

Open access

Published version of a preprint

Abstract

The clinical syndromes of frontotemporal dementia are clinically and neuropathologically heterogeneous, but processes such as neuroinflammation may be common across the disease spectrum. We investigated how neuroinflammation relates to the localization of tau and TDP-43 pathology, and to the heterogeneity of clinical disease. We used PET in vivo with (i) 11C-PK-11195, a marker of activated microglia and a proxy index of neuroinflammation; and (ii) 18F-AV-1451, a radioligand with increased binding to pathologically affected regions in tauopathies and TDP-43-related disease, and which is used as a surrogate marker of non-amyloid-β protein aggregation. We assessed 31 patients with frontotemporal dementia (10 with behavioural variant, 11 with the semantic variant and 10 with the non-fluent variant), 28 of whom underwent both 18F-AV-1451 and 11C-PK-11195 PET, and matched control subjects (14 for 18F-AV-1451 and 15 for 11C-PK-11195). We used a univariate region of interest analysis, a paired correlation analysis of the regional relationship between binding distributions of the two ligands, a principal component analysis of the spatial distributions of binding, and a multivariate analysis of the distribution of binding that explicitly controls for individual differences in ligand affinity for TDP-43 and different tau isoforms. We found significant group-wise differences in 11C-PK-11195 binding between each patient group and controls in frontotemporal regions, in both a regions-of-interest analysis and in the comparison of principal spatial components of binding. 18F-AV-1451 binding was increased in semantic variant primary progressive aphasia compared to controls in the temporal regions, and both semantic variant primary progressive aphasia and behavioural variant frontotemporal dementia differed from controls in the expression of principal spatial components of binding, across temporal and frontotemporal cortex, respectively. There was a strong positive correlation between 11C-PK-11195 and 18F-AV-1451 uptake in all disease groups, across widespread cortical regions. We confirmed this association with post-mortem quantification in 12 brains, demonstrating strong associations between the regional densities of microglia and neuropathology in FTLD-TDP (A), FTLD-TDP (C), and FTLD-Pick's. This was driven by amoeboid (activated) microglia, with no change in the density of ramified (sessile) microglia. The multivariate distribution of 11C-PK-11195 binding related better to clinical heterogeneity than did 18F-AV-1451: distinct spatial modes of neuroinflammation were associated with different frontotemporal dementia syndromes and supported accurate classification of participants. These in vivo findings indicate a close association between neuroinflammation and protein aggregation in frontotemporal dementia. The inflammatory component may be important in shaping the clinical and neuropathological patterns of the diverse clinical syndromes of frontotemporal dementia.

Overview

CoChat Summary

## TL;DR

This PET and post-mortem study found that neuroinflammation and protein aggregation co-localize across the frontotemporal dementia (FTD) spectrum, both regionally and across syndromes. The spatial pattern of neuroinflammation was disease-specific and classified FTD groups more accurately than protein-aggregation patterns.

## Key findings

  • In regional PET analyses, 11C-PK-11195 and 18F-AV-1451 binding were significantly correlated within each group: svPPA r(81) = 0.727 before control subtraction and 0.883 after; bvFTD r(81) = 0.582 before and 0.499 after; nfvPPA r(81) = 0.427 before and 0.589 after, all P < 0.0001.
  • Repeated-measures ANOVA showed significant region-by-diagnosis interactions for both tracers versus controls: 11C-PK-11195 F(37.4,423.5) = 3.54, P < 0.001 and 18F-AV-1451 F(33.6,403.6) = 3.80, P < 0.001.
  • After FDR correction, elevated 11C-PK-11195 binding was seen in bvFTD in bilateral superior frontal gyri and putamen, right nucleus accumbens, left posterior orbital gyrus, inferior frontal gyrus and middle frontal gyrus; in svPPA it was elevated in multiple temporal and related regions, and in nfvPPA no regions survived FDR correction.
  • Post-mortem immunohistochemistry showed a significant relationship between pathology density and microglia density [Wald χ2(1) = 21.40, P < 0.001], driven by amoeboid microglia [Wald χ2(1) = 30.83, P < 0.001] but not ramified microglia [Wald χ2(1) = 0.02, P = 0.898].

## Methods

  • The study used the NIMROD cohort: 31 FTD patients (10 bvFTD, 11 svPPA, 10 nfvPPA) scanned with 18F-AV-1451; 28 of these also had 11C-PK-11195 PET. Control groups included 14 participants for 18F-AV-1451 and 15 different participants for 11C-PK-11195.
  • PET data were analyzed across 83 regions of interest using repeated-measures ANOVA, regional correlations between tracers, principal component analysis, and non-parametric multi-dimensional scaling with 10-fold cross-validated linear SVM classification.
  • Quantitative post-mortem immunohistochemistry was performed on 12 cases (3 FTLD-Pick’s, 3 FTLD-TDP type C, 3 FTLD-TDP type A, 3 Braak stage V Alzheimer’s disease) across four brain regions, with generalized linear models and correlations used to relate pathology to microglia.

## Limitations

  • The paper states that the main limitation is small group size; although larger than most prior PET studies in FTD, each diagnostic group was still small, reducing power for group differences and clinical associations.
  • The authors state that genotyping and amyloid testing were only done when clinically indicated and by consent, so not all participants had direct amyloid assessment or genotyping.
  • Evident from the text: pathological subtype could not be determined in vivo, so the clinical diagnostic groups cannot be mapped cleanly onto specific proteinopathies.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1093/brain/awaa033

Cites

73 of 73 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Regional ligand binding by group. Unthresholded regional t-scores for each disease group compared to the control group for 11C-PK-11195 BPND on the left and 18F-AV-1451 BPND on the right.
Figure 1 Regional ligand binding by group. Unthresholded regional t-scores for each disease group compared to the control group for 11C-PK-11195 BPND on the left and 18F-AV-1451 BPND on the right.CC BY · PubMed Central
Figure 2 Scatter plot of the regional mean BPND for 11C-PK-11195 against regional mean BPND of 18F-AV-1451 by disease group. For each disease group raw values are demonstrated on the left with values adjusted for non-specific signal strength through subtraction of the regional control mean shown on the right.
Figure 2 Scatter plot of the regional mean BPND for 11C-PK-11195 against regional mean BPND of 18F-AV-1451 by disease group. For each disease group raw values are demonstrated on the left with values adjusted for non-specific signal strength through subtraction of the regional control mean shown on the right.CC BY · PubMed Central
Figure 3 First four principal components for 11C-PK-11195 and 18F-AV-1451. 18F-AV-1451 component 5 was also retained by Cattell’s criterion but was not strongly weighted to any region and did not discriminate groups so is omitted here for parsimony. The bottom row shows, for each principal component (PC), the difference between each patient group and controls, adjusted for age and sex in the repeated measures ANOVA. Error bars span ± 1 SEM (standard error of the mean for the patient group). Significance in post hoc tests: ***P < 0.001, **P < 0.01, *P < 0.05.
Figure 3 First four principal components for 11C-PK-11195 and 18F-AV-1451. 18F-AV-1451 component 5 was also retained by Cattell’s criterion but was not strongly weighted to any region and did not discriminate groups so is omitted here for parsimony. The bottom row shows, for each principal component (PC), the difference between each patient group and controls, adjusted for age and sex in the repeated measures ANOVA. Error bars span ± 1 SEM (standard error of the mean for the patient group). Significance in post hoc tests: ***P < 0.001, **P < 0.01, *P < 0.05.CC BY · PubMed Central
Figure 4 Pairwise classification accuracy for each ligand. 11C-PK-11195 (left), 18F-AV-1451 (middle), and using combined data (right). The graphs represent a 2D projection of the between-individual PET signal distribution dissimilarity calculated according to the squared metric stress criterion. A 10-fold cross-validated support vector machine was applied to each plot, and the classification accuracy compared to a null distribution of 1000 randomizations for non-parametric significant testing. For each comparison, percentage classification and P-value is stated. In simple terms, this means that the similarity of the distribution of ligand binding across the brain for each individual was assessed irrespective of the absolute magnitude of binding (and therefore not determined by differences in ligand affinity for different pathological subtypes). Note how in the top left plot (nfvPPA versus svPPA for 11C-PK-11195) two groups of patients are clearly separated. By contrast, in the second column third row (bvFTD versus nfvPPA for 18F-AV-1451) the points are intermingled, with only chance-level classification.
Figure 4 Pairwise classification accuracy for each ligand. 11C-PK-11195 (left), 18F-AV-1451 (middle), and using combined data (right). The graphs represent a 2D projection of the between-individual PET signal distribution dissimilarity calculated according to the squared metric stress criterion. A 10-fold cross-validated support vector machine was applied to each plot, and the classification accuracy compared to a null distribution of 1000 randomizations for non-parametric significant testing. For each comparison, percentage classification and P-value is stated. In simple terms, this means that the similarity of the distribution of ligand binding across the brain for each individual was assessed irrespective of the absolute magnitude of binding (and therefore not determined by differences in ligand affinity for different pathological subtypes). Note how in the top left plot (nfvPPA versus svPPA for 11C-PK-11195) two groups of patients are clearly separated. By contrast, in the second column third row (bvFTD versus nfvPPA for 18F-AV-1451) the points are intermingled, with only chance-level classification.CC BY · PubMed Central
Figure 5 Immunohistochemistry from cases with FTLD-TDP43 types A and C, FTLD-P (Pick’s disease), and Alzheimer’s disease (AD) at Braak stage V. Areas of low (visual cortex BA17/18) and high (temporal cortex, BA21/22) disease burden are shown. Scale bars = 100 µm. Representative micrographs from the same location on adjacent sections stained for the relevant protein aggregate (phosphorylated-tau or TDP43) and CD68 (expressed by microglia), respectively.
Figure 5 Immunohistochemistry from cases with FTLD-TDP43 types A and C, FTLD-P (Pick’s disease), and Alzheimer’s disease (AD) at Braak stage V. Areas of low (visual cortex BA17/18) and high (temporal cortex, BA21/22) disease burden are shown. Scale bars = 100 µm. Representative micrographs from the same location on adjacent sections stained for the relevant protein aggregate (phosphorylated-tau or TDP43) and CD68 (expressed by microglia), respectively.CC BY · PubMed Central
Figure 6 The relationship between protein aggregation and microglia in each post-mortem sample. Densities are quantified as the number of microglia or pathological inclusions per square millimetre. Each point represents a single brain region in a single individual. The Pearson correlation (r), and the partial correlation (ρ) after factoring out the density of cell nuclei are shown for each relationship, along with the corresponding P-value. Trend lines are emboldened when both correlation and partial correlation were significant at α < 0.05.
Figure 6 The relationship between protein aggregation and microglia in each post-mortem sample. Densities are quantified as the number of microglia or pathological inclusions per square millimetre. Each point represents a single brain region in a single individual. The Pearson correlation (r), and the partial correlation (ρ) after factoring out the density of cell nuclei are shown for each relationship, along with the corresponding P-value. Trend lines are emboldened when both correlation and partial correlation were significant at α < 0.05.CC BY · PubMed Central

Verification

Claims the paper makes

24 Valid · 1 Not valid · 7 Not checked · 99 Own results and interpretations

60 more claims · 1 with their cited sources checked

Create a free account to see all 131 claims and to verify the 3 references still open.

See all claims — free account
  • Probably not a substantial claim. 23
  • It may state two separate claims as one. 51
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Statistics recomputed

Every reported test result, recomputed from its test statistic and degrees of freedom. A result shows as not adding up only once an independent check has confirmed it.

  • ConsistentF(37.4, 423.5) = 3.54reported p < .001 · recomputed p < .001

    “F(37.4,423.5) = 3.54, p < .001”

  • ConsistentF(33.6, 403.6) = 3.8reported p < .001 · recomputed p < .001

    “F(33.6,403.6) = 3.80, p < .001”

  • ConsistentF(2, 3) = 8.26reported p = .06 · recomputed p = .060

    “F(2,3) = 8.26, p = .060”

  • ConsistentF(5.3, 7.8) = 1.47reported p = .3 · recomputed p = .299

    “F(5.3,7.8) = 1.47, p = .300”

  • ConsistentF(2, 4) = 0.85reported p = .492 · recomputed p = .492

    “F(2,4) = 0.85, p = .492”

5 of 68 · the rest aren’t loaded

63 more recomputed tests

Create a free account to see every test the Stats check recomputed.

See all tests — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Self-check results appear here once an independent check has confirmed them.

Citations

Cites

Show all 79 references

Cited by

See all 124

Metadata

Authors
Bevan-Jones, W. R., Cope, T. E., Jones, P. S., Kaalund, S. S., Passamonti, L., Allinson, K., Green, O., Hong, Y. T., Fryer, T. D., Arnold, R., Coles, J. P., Aigbirhio, F. I., Larner, A. J., Patterson, K., O’Brien, J. T., & Rowe, J. B.
Affiliations
  • University of Cambridge (GB)
  • MRC Cognition and Brain Sciences Unit (GB)
  • Cambridge University Hospitals NHS Foundation Trust (GB)
  • Institute of Molecular Bioimaging and Physiology (IT)
  • Walton Centre (GB)
  • Department of Psychiatry, University of Cambridge, Cambridge, UK
Corresponding author
Cope, Thomas E
Venue
Brain
Published
2020-03-01
Volume
143
Issue
3
Pages
1010-1026
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
OpenAlex
W3011374615
Cited by
124
References
79
Citations by year
2026: 17 · 2025: 15 · 2024: 19 · 2023: 17 · 2022: 21 · 2021: 18 · 2020: 16
FWCI
13.11
Type
journal article
Language
en
Open access
Locations
  • Brain (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Apollo (University of Cambridge) (submittedVersion, cc-by)
  • Apollo (cc-by)
Funders
  • National Institute for Health Research Cambridge Biomedical Research Centre
  • Cambridge Brain Bank
  • Wellcome Trust (103838)
  • Cambridge Centre for Parkinson-plus; the Medical Research Council (MR/P01271X/1)
  • National Institute for Health Research, Association of British Neurologists
  • Patrick Berthoud Charitable Trust
  • Lundbeck Foundation
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
frontotemporal dementia, neuroinflammation, microglial activation, tau pathology, TDP-43 pathology, protein aggregation, 18F-AV-1451, positron emission tomography, semantic dementia, behavioral variant frontotemporal dementia
MeSH terms
Aged, Carbolines, Carbon Radioisotopes, DNA-Binding Proteins, Female, Humans, Inflammation, Isoquinolines, Male, Middle Aged, Protein Binding, Case-Control Studies, Microglia, Tauopathies, Positron-Emission Tomography, Frontotemporal Dementia, Protein Aggregates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrum. https://app.cochat.ai/papers/10.1093/brain/awaa033
The paper
Bevan-Jones, W. R., Cope, T. E., Jones, P. S., Kaalund, S. S., Passamonti, L., Allinson, K., Green, O., Hong, Y. T., Fryer, T. D., Arnold, R., Coles, J. P., Aigbirhio, F. I., Larner, A. J., Patterson, K., O’Brien, J. T., & Rowe, J. B. (2020). Neuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrum. Brain. https://doi.org/10.1093/brain/awaa033

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.